Upgrade to SI Premium - Free Trial

Leerink Partners on Eli Lilly (LLY) following Retatrutide data

March 19, 2026 2:52 PM
Leerink Partners analyst David Risinger reiterated an Outperform rating and $1,296.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments